We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction (AMICI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01781390
Recruitment Status : Completed
First Posted : February 1, 2013
Results First Posted : January 18, 2022
Last Update Posted : June 23, 2022
Sponsor:
Information provided by (Responsible Party):
Mesoblast, Ltd. ( Mesoblast, Inc. )

Tracking Information
First Submitted Date  ICMJE January 14, 2013
First Posted Date  ICMJE February 1, 2013
Results First Submitted Date  ICMJE December 17, 2021
Results First Posted Date  ICMJE January 18, 2022
Last Update Posted Date June 23, 2022
Actual Study Start Date  ICMJE March 11, 2013
Actual Primary Completion Date April 6, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 17, 2021)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to approximately 8 years ]
Safety measure: An AE is any unfavorable and unintended sign, symptom, or disease, whether or not related to the investigational product. A TEAE was defined as any AE with onset post study drug treatment. An SAE was defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically important.
Original Primary Outcome Measures  ICMJE
 (submitted: January 30, 2013)
Frequency of the total major adverse cardiac and cerebrovascular events (MACCE) [ Time Frame: 24 months ]
Occurrence of MACCE events including cardiac death, myocardial infarction, target vessel revascularization, stroke, new or worsening congestive heart failure during index hospitalization and cardiac hospitalizations due to congestive heart failure.
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
Official Title  ICMJE A Prospective, Double-Blind, Randomized, Placebo-controlled Clinical Trial of Intracoronary Infusion of Mesenchymal Precursor Cells (MPC) in the Treatment of Patients With ST-Elevation Myocardial Infarction
Brief Summary

This was a double-blind, randomized, placebo-controlled study that was designed to enroll a total of 225 participants with de novo anterior wall acute ST-segment elevation myocardial infarction (STEMI) due to a lesion of the left anterior descending coronary artery undergoing percutaneous coronary intervention (PCI). Eligible participants were to be enrolled and undergo revascularization of the culprit left anterior descending (LAD) coronary artery. The interventional procedure included as dose ranging assessment of intracoronary (IC) delivery of MPC or placebo infused into the stented coronary artery. This study compared two doses of MPCs and a placebo control group. Study participants were randomly assigned in 1:1:1 fashion to receive either 12.5 Million or 25 Million MPCs or placebo (saline). Initially, each group was designed to have approximately 75 patients per treatment group. The Primary Objective of the study was to determine the safety and feasibility of IC infusion of investigational MPCs in this acute STEMI population.

The Primary Objective of the study was to determine the safety and feasibility of IC infusion of investigational MPCs in this acute STEMI population. Feasibility of the infusion of the investigational agent was assessed by measurement of thrombolysis in myocardial infarction (TIMI) flow and perfusion (1) immediately prior to, (2) during (after approximately 50% of total investigational agent volume infused) and (3) following the investigational agent infusion after successful PCI and stenting. There was no evidence of clinically important coronary microvascular obstruction related to infusion of the investigational agent.

Detailed Description

This was a prospective, double-blind, randomized, placebo-controlled study that was designed to enroll approximately 225 participants with de novo anterior STEMI due to a lesion involving the proximal-mid LAD coronary artery who undergo primary PCI at approximately 45 clinical study sites. However, due to difficulty in consenting participants and operationalizing the protocol under the emergency environment of an acute STEMI, it became clear that a major protocol amendment would be required. Accordingly, the protocol was adjusted to randomize 105 participants (35 per treatment group) at 25 clinical study sites. This 53% reduction in participants from the original protocol allowed preliminary evaluations of safety and feasibility.

Potential participants who were in the midst of experiencing an acute anterior wall STEMI, where increased time to coronary revascularization is known to correlate with the extent of subsequent myocardial necrosis, were approached by a study site investigator prior to PCI to determine the participant's interest to participate in a stem cell investigational trial. This required the patient to sign an informed consent permitting both the PCI procedure and participation in the trial. Participants who agreed to participate in the AMICI study and had a successful and uneventful PCI and stenting of the culprit LAD lesion performed were then randomized to one of the three treatment groups. The randomization and treatment assignment were obtained using an interactive voice-response system (IVRS/interactive web response system [IWRS]). The following stratification for duration of cardiac ischemia was performed to ensure balanced randomization across the treatment groups:

  • ≤2 hours
  • >2 hours to ≤6 hours
  • >6 to ≤12 hours

Eligible participants received intracoronary delivery of the assigned treatment infused via a microcatheter into the stented culprit artery.

After approximately 50% of the intracoronary infusion of investigational treatment was completed, an angiographic determination of coronary flow was performed. The following guidelines were used to determine if the remaining investigational agent should be infused:

The study infusion should have been continued if TIMI 2 or TIMI 3 flow was present in the absence of ALL of the following;

  • Sustained hypotension not responsive to fluid administration;
  • Clinical signs/symptoms indicating an acute cerebrovascular event;
  • Re-elevation of ST-segments if previously resolved with PCI;
  • Onset of the participant's symptoms of myocardial ischemia unresponsive to appropriate interventions;
  • Two episodes of sustained ventricular tachycardia (VT)/ventricular fibrillation (VF) requiring cardioversion (infusion can continue if a single episode of sustained VT/VF requiring cardioversion occurred).

Feasibility of the infusion of the investigational agent was assessed by measurement of TIMI flow and perfusion (1) immediately prior to, (2) during (after approximately 50% of total investigational agent volume infused) and (3) following the investigational agent infusion after successful PCI and stenting. There was no evidence of clinically important coronary microvascular obstruction related to infusion of the investigational agent.

If, for any reason, the site investigator withdrew a randomized participant prior to infusion of the investigational agent, the reason for early termination and data from the screening visit were entered into the eCRF by the study site. The participant did not remain in the study. If for any reason, a participant's study infusion was halted due to safety considerations, the participant remained in the study. A participant who prematurely withdrew from the study remained in the study for long-term safety follow-up.

Evaluation for safety was performed for up to 24 months post infusion for all non-Swedish sites. Participants enrolled in Sweden who consented for additional follow-up underwent safety assessments at 36, 48, and 60 months post-infusion of investigational agent. All participants were to have cardiac imaging using cardiac magnetic resonance imaging [cMRI] and 2D-echocardiography, Holter monitoring, clinical evaluations, and laboratory testing as outlined in the study protocol.

An independent Data Monitoring Safety Board (DSMB) reviewed all relevant acute peri-procedural data, serious adverse events (SAE), other adverse events (AE), and efficacy data (if requested) periodically until participant enrolment was closed.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Acute Myocardial Infarction
Intervention  ICMJE
  • Other: Placebo
    Matching placebo solution for infusion.
  • Biological: Mesenchymal Precursor Cells (MPC) 12.5 M
    MPC 12.5 M solution for infusion.
  • Biological: Mesenchymal Precursor Cells (MPC) 25 M
    MPC 25 M solution for infusion.
Study Arms  ICMJE
  • Placebo Comparator: Placebo
    Participants received matching-placebo solution 2 milliliters per minute (mL/min) infused Intracoronary for 60 min including line flush [0 Mesenchymal Precursor Cells (MPCs)/min] on Day 0.
    Intervention: Other: Placebo
  • Experimental: Mesenchymal Precursor Cells (MPC) 12.5 M
    Participants received MPC 12.5 solution 2 mL/min infused Intracoronary for 60 min including line flush (2.5x10^5 MPCs/min) on Day 0.
    Intervention: Biological: Mesenchymal Precursor Cells (MPC) 12.5 M
  • Experimental: Mesenchymal Precursor Cells (MPC) 25 M
    Participants received MPC 12.5 solution 2 mL/min infused Intracoronary for 60 min including line flush (5.0x10^5 MPCs/min) on Day 0.
    Intervention: Biological: Mesenchymal Precursor Cells (MPC) 25 M
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 17, 2021)
106
Original Estimated Enrollment  ICMJE
 (submitted: January 30, 2013)
225
Actual Study Completion Date  ICMJE April 6, 2021
Actual Primary Completion Date April 6, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria:

  • Clinical symptoms consistent with acute myocardial infarct (AMI) (pain, etc.) for a maximum of 12 hours from onset of symptoms to percutaneous coronary intervention (PCI).
  • De Novo anterior AMI.
  • Successful revascularization of the culprit lesion.

Key Exclusion Criteria:

  • Prior AMI, known cardiomyopathy, or hospital admission for heart failure (HF).
  • Significant valvular disease.
  • Need for other interventional or surgical procedure to treat heart disease (planned or scheduled).
  • Cardiogenic shock or hemodynamic instability within 24 hours of randomization.
  • Prior PCI to LAD.
  • Pacemaker, ICD (Implantable Cardioverter Defibrillator), or any other contra-indication for cardiac MRI.
  • Prior or current participation in any stem cell study or any other investigational trial in the past 30 days.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries Australia,   Belgium,   Denmark,   Netherlands,   New Zealand
 
Administrative Information
NCT Number  ICMJE NCT01781390
Other Study ID Numbers  ICMJE ANG.AMI-IC001
2010-020497-41 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Mesoblast, Ltd. ( Mesoblast, Inc. )
Original Responsible Party Angioblast Systems
Current Study Sponsor  ICMJE Mesoblast, Inc.
Original Study Sponsor  ICMJE Angioblast Systems
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Fred Grossman, DO Mesoblast, Inc.
PRS Account Mesoblast, Ltd.
Verification Date June 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP